# US Mendelian Disorders Testing Market

> US Mendelian disorders testing market research report: by test type (carrier testing, diagnostic testing, new-born screening), by disorder (cystic fibrosis, sickle cell anemia), by end-user (hospitals, ascs, specialized clinics) – Global forecast till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.2%
- **2024:** $ 0.58 Billion
- **2025:** $ 0.63 Billion
- **2035:** $ 1.39 Billion
- **Key Players:** Invitae Corporation (US), Myriad Genetics, Inc. (US), GeneDx, Inc. (US), Ambry Genetics Corporation (US), Fulgent Genetics, Inc. (US), Natera, Inc. (US), 23andMe, Inc. (US), Color Genomics, Inc. (US), PathAI, Inc. (US)

**Report ID:** MRFR/LS/11203-CR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 02, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-mendelian-disorders-testing-market-12728

---

## Market Summary

## US Mendelian disorders testing Market Highlighted Trends & Dynamics

As per MRFR analysis, the Size was estimated at 0.58 (USD Billion) in 2024. The Industry is expected to grow from 0.63 (USD Billion) in 2025 to 1.29 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 8.02% during the forecast period (2025 - 2034).

The US Mendelian Disorders Testing market is undergoing significant transformations as advancements in genetic testing technologies continue to redefine the landscape. Mendelian disorders, characterized by single-gene mutations, pose unique challenges in diagnosis and management. This article explores key aspects of the US Mendelian Disorders Testing market, including market share, demand, supply chain dynamics, competitive landscape, and an overview of the industry.

Market Share and Analysis: Understanding market share is crucial in comprehending the competitive dynamics within the Mendelian Disorders Testing market. Various players, including diagnostic laboratories, genetic testing companies, and research institutions, contribute to the diverse ecosystem. Market leaders have carved out their niches by offering comprehensive testing panels, innovative technologies, and reliable genetic counseling services. The distribution of market share is reflective of the diverse approaches and technologies embraced by these entities to address the complexities of Mendelian disorders. 

Demand for Mendelian Disorders Testing: The demand for Mendelian Disorders Testing has experienced a notable upswing due to several factors. Firstly, increased awareness among healthcare providers and patients about the genetic basis of certain disorders has driven demand. Additionally, advancements in sequencing technologies have made genetic testing more accessible and affordable. As individuals and families seek a better understanding of their genetic predispositions, the demand for Mendelian Disorders Testing has grown, underscoring the pivotal role of genetic information in personalized medicine. 

Overview of Mendelian Disorders Testing: Mendelian Disorders Testing involves the analysis of specific genes associated with single-gene disorders inherited in a Mendelian fashion, such as autosomal dominant, autosomal recessive, or X-linked patterns. The testing process typically includes DNA extraction, sequencing, and variant analysis. Clinicians utilize the results to diagnose, predict, and manage genetic disorders. The scope of testing encompasses a wide array of conditions, ranging from rare genetic diseases to more prevalent disorders with a Mendelian inheritance pattern. 

Supply Chain Dynamics: The supply chain in Mendelian Disorders Testing involves a complex interplay of entities ranging from diagnostic laboratories and testing kit manufacturers to genetic counselors and healthcare providers. Genetic testing kits, which include sample collection materials and shipping components, are produced by manufacturers and distributed to testing laboratories. The testing process involves a series of steps, from sample collection to data analysis, requiring collaboration between various stakeholders to ensure accuracy and reliability in results. The efficiency of the supply chain is critical in meeting the growing demand for Mendelian Disorders Testing. 

Competitive Landscape: The competitive landscape of Mendelian Disorders Testing is characterized by a mix of established diagnostic companies, niche players, and emerging startups. Established laboratories with extensive experience in genetic testing often dominate market share. However, innovative startups focusing on specialized testing panels or leveraging cutting-edge technologies have also gained prominence. The competition is not only centered around the accuracy and comprehensiveness of testing but also on the ability to offer genetic counseling services and integrate new technologies such as next-generation sequencing into routine clinical practice. 

Industry Overview: The Mendelian Disorders Testing industry in the US is at the forefront of precision medicine, driving advancements in diagnosis and treatment strategies. The industry's growth is propelled by ongoing research and development efforts, collaborations between academic institutions and industry players, and the integration of genetic testing into mainstream healthcare. As the understanding of Mendelian disorders expands, the industry is poised for further innovation, with a focus on improving testing methodologies, expanding test panels, and enhancing the overall accessibility of genetic information.

## Market Drivers

### Evolving Regulatory Environment

The regulatory landscape surrounding genetic testing is evolving, which has implications for the US Mendelian Disorders Testing Market. Recent updates in policies and guidelines from regulatory bodies, such as the Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS), are aimed at ensuring the safety and efficacy of genetic tests. These changes are fostering a more structured environment for the development and commercialization of genetic testing products. As regulations become more defined, companies are likely to invest in research and development to comply with these standards, potentially leading to an influx of innovative testing solutions. This regulatory evolution not only enhances consumer confidence but also encourages healthcare providers to adopt genetic testing as a standard practice, thereby propelling market growth.

### Rising Prevalence of Genetic Disorders

The rising prevalence of genetic disorders is a critical driver for the US Mendelian Disorders Testing Market. Recent statistics indicate that approximately 1 in 10 individuals in the US are affected by a genetic condition, underscoring the urgent need for effective testing solutions. This increasing prevalence is prompting healthcare providers to recommend genetic testing more frequently, as it plays a vital role in diagnosis and management. Moreover, the growing recognition of the importance of genetic counseling is contributing to the demand for testing services. As more individuals seek to understand their genetic risks, the market is likely to witness sustained growth. The combination of rising prevalence and increased healthcare provider recommendations is creating a robust environment for the expansion of the US Mendelian Disorders Testing Market.

### Increased Investment in Genetic Research

Investment in genetic research is on the rise, significantly impacting the US Mendelian Disorders Testing Market. Public and private funding for genetic research initiatives has surged, with government agencies allocating substantial resources to understand the genetic basis of various disorders. This influx of funding is facilitating the development of advanced testing methodologies and expanding the scope of genetic testing services. For instance, the National Institutes of Health (NIH) has reported a 15% increase in funding for genetic research projects over the past year. Such investments are likely to lead to breakthroughs in the identification and treatment of Mendelian disorders, thereby enhancing the overall market landscape. As research continues to unveil new genetic insights, the demand for comprehensive testing solutions is expected to grow, further driving market expansion.

### Technological Advancements in Genetic Testing

The US Mendelian Disorders Testing Market is experiencing a transformative phase due to rapid technological advancements in genetic testing methodologies. Innovations such as next-generation sequencing (NGS) and whole exome sequencing (WES) have significantly enhanced the accuracy and efficiency of genetic testing. These technologies allow for the simultaneous analysis of multiple genes, which is particularly beneficial for identifying Mendelian disorders. As a result, the market is projected to grow at a compound annual growth rate (CAGR) of approximately 10% over the next five years. Furthermore, the integration of artificial intelligence in data analysis is streamlining the interpretation of complex genetic data, thereby improving diagnostic outcomes. This technological evolution not only facilitates earlier detection of genetic disorders but also supports personalized treatment plans, making it a pivotal driver in the US Mendelian Disorders Testing Market.

### Growing Awareness and Demand for Early Diagnosis

There is a notable increase in awareness regarding genetic disorders and the importance of early diagnosis within the US Mendelian Disorders Testing Market. Educational initiatives and advocacy from healthcare professionals have contributed to a heightened understanding of Mendelian disorders among the general public. This growing awareness is leading to an increase in demand for genetic testing services, as individuals seek proactive measures to identify potential genetic risks. According to recent surveys, nearly 60% of respondents expressed a desire for genetic testing to understand their health better. This trend is further supported by the rising prevalence of genetic disorders, which has been estimated to affect approximately 1 in 300 individuals in the US. Consequently, the demand for early diagnosis is driving market growth, as families and individuals prioritize genetic testing to inform healthcare decisions.

## Future Outlook

The US [Mendelian Disorders Testing Market](https://www.marketresearchfuture.com/reports/mendelian-disorders-testing-market-5500) is projected to grow at an 8.2% CAGR from 2025 to 2035, driven by advancements in genetic research, increased awareness, and technological innovations.

**New opportunities:**

- Development of AI-driven genetic analysis platforms
- Expansion of telehealth services for genetic counseling
- Partnerships with pharmaceutical companies for targeted therapies

By 2035, the market is expected to be robust, driven by innovation and strategic partnerships.

## Segment Insights

### By Type: Carrier Testing (Largest) vs. Diagnostic Testing (Fastest-Growing)

In the US mendelian disorders-testing market, carrier testing has established itself as the largest segment, capturing a significant share due to its key role in assessing genetic risks prior to conception. This segment predominantly appeals to couples planning families, ensuring that potential genetic disorders are identified early on. Cross-analysis with other testing types shows that diagnostic testing follows closely, providing critical information for individuals already affected by a condition, further reinforcing the importance of accurate genetic knowledge in this sector.

Looking forward, the growth trends indicate that diagnostic testing is the fastest-growing segment, driven by advancements in technology and increasing public awareness of genetic disorders. Furthermore, policy changes promoting screening and testing, coupled with a growing emphasis on personalized medicine, are expected to bolster this expansion. The rising prevalence of genetic disorders is introducing more patients to diagnostic testing, which will ultimately strengthen the market's overall landscape.

Carrier Testing: Dominant vs. Diagnostic Testing: Emerging

Carrier testing stands out as a dominant force in the US mendelian disorders-testing market, primarily due to its wide application among prospective parents. This segment offers a clear understanding of the chances of passing on genetic conditions, making it crucial for family planning decisions. On the other hand, diagnostic testing is emerging as a key player, fueled by innovative technologies and a deeper understanding of genetic conditions. It is increasingly being adopted by patients seeking clarity regarding existing health issues, thus driving market growth. Both segments play integral roles, with carrier testing focusing on prevention and diagnostic testing providing immediate insights for those affected.

### By Disorder Type: Cystic Fibrosis (Largest) vs. Sickle Cell Anemia (Fastest-Growing)

In the US mendelian disorders-testing market, cystic fibrosis remains the largest segment, capturing significant attention from healthcare providers and patients alike due to its severe implications and the need for early diagnosis. Following closely, sickle cell anemia is emerging as a crucial contender, gaining increased focus in testing and research, especially in diverse populations where the prevalence is notable. Overall, the distribution indicates a strong inclination towards disorders that exhibit clear diagnostic criteria and management plans.

Growth trends in the US mendelian disorders-testing market are being driven by advancements in genetic testing technologies, increasing awareness about rare genetic diseases, and the rising incidence of disorders such as sickle cell anemia. The fast-growing segment of sickle cell anemia has seen rising support from healthcare initiatives aimed at improving screenings, particularly in affected communities. Additionally, the continuous decline in testing costs and the expansion of insurance coverage for genetic testing are expected to fuel further growth in this segment.

Cystic Fibrosis: Dominant vs. Sickle Cell Anemia: Emerging

Cystic fibrosis stands as a dominant disorder type in testing due to its high clinical relevance and the requirement for rapid diagnosis to manage its life-altering effects. The ongoing research and development in treatment therapies contribute to sustaining its prominence in the US mendelian disorders-testing market. On the other hand, sickle cell anemia, characterized by significant morbidity and healthcare burdens, is emerging rapidly as a focus of testing due to an increase in awareness and the necessity for targeted interventions. The implementation of comprehensive screening programs has accelerated its recognition, fostering a growing market that is expected to gain momentum with advancements in diagnostic methodologies and patient care strategies.

### By End User: Hospitals (Largest) vs. Specialized Clinics (Fastest-Growing)

In the US mendelian disorders-testing market, hospitals dominate the end user segment, accounting for the largest share due to their extensive resources and comprehensive diagnostic facilities. Ambulatory surgical centers (ASCs) also play a significant role, providing pivotal testing services, while specialized clinics carve out a niche with tailored services targeting specific disorders and patient needs.

The growth trends in this segment are being driven by an increasing demand for personalized medicine and advancements in genetic testing technologies. Specialized clinics are experiencing the fastest growth as they adapt quickly to new testing methodologies and cater to the unique needs of patients. ASCs are also expanding their capabilities, capitalizing on the shift towards outpatient care, which boosts their market position.

Hospitals (Dominant) vs. Specialized Clinics (Emerging)

Hospitals serve as the dominant force within the end user segment, attributed to their capacity to offer a broad spectrum of medical services including extensive diagnostic testing. These institutions benefit from large-scale operations, advanced technology, and skilled personnel, enabling efficient management of complex cases. In contrast, specialized clinics are emerging as key players, focusing on specific mendelian disorders and leveraging their expertise to provide personalized care. Their flexibility and adaptability to new testing methods allow them to respond swiftly to market demands, enhancing their appeal among patients seeking targeted services. This dynamic interplay between hospitals and specialized clinics shapes the overall landscape of the US mendelian disorders-testing market.

## Competitive Benchmarking

The [mendelian disorders-testing market](https://www.marketresearchfuture.com/reports/mendelian-disorders-testing-market-5500) is characterized by a dynamic competitive landscape, driven by advancements in genetic testing technologies and an increasing demand for personalized medicine. Key players such as Illumina (US), Thermo Fisher Scientific (US), and Myriad Genetics (US) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. Illumina (US) focuses on expanding its genomic sequencing capabilities, while Thermo Fisher Scientific (US) emphasizes the integration of advanced analytics into its testing solutions. Myriad Genetics (US) is actively pursuing collaborations to broaden its test offerings, thereby shaping a competitive environment that prioritizes technological advancement and customer-centric solutions.
In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Roche (CH) and Invitae (US) suggests a trend towards consolidation, as these firms seek to leverage their resources and capabilities to gain a competitive edge.
In October 2025, Illumina (US) announced a strategic partnership with a leading healthcare provider to enhance access to genetic testing services. This collaboration is expected to facilitate the integration of genomic data into clinical workflows, thereby improving patient outcomes and expanding Illumina's market reach. The strategic importance of this partnership lies in its potential to streamline the testing process and promote the adoption of personalized medicine.
In September 2025, Myriad Genetics (US) launched a new suite of tests aimed at identifying rare mendelian disorders. This initiative not only diversifies its product portfolio but also positions the company as a leader in the niche market of rare genetic conditions. The launch reflects a strategic focus on addressing unmet medical needs and enhancing patient care through innovative testing solutions.
In August 2025, Thermo Fisher Scientific (US) unveiled a new digital platform designed to facilitate the analysis of genetic data. This platform aims to integrate artificial intelligence (AI) capabilities, enabling more accurate interpretations of genetic tests. The introduction of this technology underscores the company's commitment to digital transformation and its potential to redefine the landscape of genetic testing.
As of November 2025, current trends in the mendelian disorders-testing market indicate a strong emphasis on digitalization, sustainability, and AI integration. Strategic alliances are increasingly shaping the competitive landscape, fostering innovation and collaboration among key players. Looking ahead, competitive differentiation is likely to evolve, with a shift from price-based competition to a focus on technological innovation, reliability in supply chains, and the ability to deliver personalized solutions. This evolution suggests that companies will need to continuously adapt and innovate to maintain their competitive positions in a rapidly changing market.

## Report Scope

| MARKET SIZE 2024 | 0.5843(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 0.6322(USD Billion) |
| MARKET SIZE 2035 | 1.391(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.2% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Invitae Corporation (US), Myriad Genetics, Inc. (US), GeneDx, Inc. (US), Ambry Genetics Corporation (US), Fulgent Genetics, Inc. (US), Natera, Inc. (US), 23andMe, Inc. (US), Color Genomics, Inc. (US), PathAI, Inc. (US) |
| Segments Covered | test type, disorder, end-user |
| Key Market Opportunities | Advancements in genomic technologies enhance accuracy and accessibility in the US Mendelian Disorders Testing Market. |
| Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the US Mendelian Disorders Testing Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the US mendelian disorders-testing market?**
A: The market valuation was $105.35 Million in 2024.

**Q: What is the projected market size for the US mendelian disorders-testing market by 2035?**
A: The market is projected to reach $300.88 Million by 2035.

**Q: What is the expected CAGR for the US mendelian disorders-testing market during the forecast period?**
A: The expected CAGR is 10.01% from 2025 to 2035.

**Q: Which companies are the key players in the US mendelian disorders-testing market?**
A: Key players include Illumina, Thermo Fisher Scientific, Agilent Technologies, Roche, PerkinElmer, Myriad Genetics, Invitae, Fulgent Genetics, and GeneDx.

**Q: What are the main segments of the US mendelian disorders-testing market?**
A: The main segments include carrier testing, diagnostic testing, new-born screening, predictive & pre-symptomatic testing, prenatal testing, and others.

**Q: How does the carrier testing segment perform in terms of valuation?**
A: The carrier testing segment had a valuation range of $15.0 Million to $40.0 Million.

**Q: What is the valuation range for diagnostic testing in the US mendelian disorders-testing market?**
A: The diagnostic testing segment had a valuation range of $30.0 Million to $90.0 Million.

**Q: Which disorder types are most prevalent in the US mendelian disorders-testing market?**
A: Prevalent disorder types include cystic fibrosis, sickle cell anemia, and severe combined immunodeficiency (SCID), among others.

**Q: What is the expected performance of the new-born screening segment?**
A: The new-born screening segment is projected to have a valuation range of $20.0 Million to $50.0 Million.

**Q: Which end users are primarily involved in the US mendelian disorders-testing market?**
A: Primary end users include hospitals, ambulatory surgical centers (ASCs), and specialized clinics.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-mendelian-disorders-testing-market-12728*